Standard Mydrin-P
ApprovedSmall molecule
Standard Mydrin-P is one of 83 small molecule programs targeting Retinopathy of Prematurity. It is currently in Approved.
3
Indications
3
Total Trials
2
Active Trials
82
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1053 competitors in Influenza
#DrugCompanyPhaseTrials
1Standard Mydrin-P
TThe University of Hong Kong
Approved
Fluzone
SanofiPreclinical
Fluzone
GSKPreclinical
Trexall
Alnylam PharmaceuticalsPreclinical
Avigan
AAppili Therapeutics Inc.
Preclinical
Quadrivalent Influenza Vaccine
SanofiPreclinical
COMIRNATY
PfizerPreclinical
Antihistamine
Arrowhead PharmaceuticalsPreclinical
Influenza A/H5N1
NNational Institute of Allergy and Infectious Diseases (NIAID)
Preclinical
PD-1/PD-L1 Inhibitors
CChuangzhen Chen
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Standard Mydrin-P. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- TThe University of Hong Kong